U.S. Markets closed

Bio-Rad Laboratories, Inc. (BIO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
736.47-3.04 (-0.41%)
At close: 4:03PM EDT
736.48 +0.01 (0.00%)
After hours: 05:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close739.51
Open742.96
Bid655.55 x 1100
Ask736.68 x 800
Day's Range720.31 - 746.02
52 Week Range472.84 - 756.52
Volume130,901
Avg. Volume127,061
Market Cap22.054B
Beta (5Y Monthly)0.81
PE Ratio (TTM)5.42
EPS (TTM)135.87
Earnings DateOct 27, 2021 - Nov 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est755.00
  • Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised
    Zacks

    Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised

    Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.

  • Bio-Rad Laboratories, inc (BIO) Q2 2021 Earnings Call Transcript
    Motley Fool

    Bio-Rad Laboratories, inc (BIO) Q2 2021 Earnings Call Transcript

    Today, we will review the second quarter 2021 financial results and provide an update on key business trends for Bio-Rad. With me on the phone today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vice President and Chief Financial Officer; Andy Last, Executive Vice President and Chief Operating Officer; Annette Tumolo, President of the Life Science Group; and Dara Wright, President of the Clinical Diagnostics Group.

  • Bio-Rad Laboratories (BIO) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Bio-Rad Laboratories (BIO) Q2 Earnings and Revenues Beat Estimates

    Bio-Rad (BIO) delivered earnings and revenue surprises of 86.32% and 17.29%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?